Inflexibility of AMPK-mediated metabolic reprogramming in mitochondrial disease

Dar-Shong Lin1,2, Shu-Huei Kao3, Che-Sheng Ho1

  • 1Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan.

Oncotarget
|November 2, 2017
PubMed

Insights

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome cells struggle to switch fuel sources. Energy deficiency increases glycolysis, hindering fatty acid use and contributing to disease.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Genetics

Background:

  • Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome, often caused by the A3243G mitochondrial DNA mutation, involves complex metabolic dysregulation.
  • The adaptive mechanisms for switching between glucose and fatty acid metabolism in response to energy deficits in MELAS syndrome are not fully understood.

Purpose of the Study:

  • To investigate the metabolic fuel preferences and adaptive responses in MELAS syndrome fibroblasts under energy-deficient conditions.
  • To elucidate the role of the AMP-activated protein kinase (AMPK) signaling pathway in regulating cellular metabolism and biogenesis in MELAS syndrome.

Main Methods:

  • Analysis of electron transport chain complex activity, cellular biogenesis, ATP synthesis, and fatty acid oxidation in MELAS fibroblasts.
  • Assessment of glycolytic flux, AMPK pathway activation, and transcriptional modulation of metabolic enzymes and biogenesis factors.

Main Results:

  • MELAS fibroblasts exhibit deficiencies in electron transport chain complexes I and IV, impaired biogenesis under glucose deprivation, and reduced ATP synthesis.
  • Fatty acid oxidation is attenuated, with energy production primarily relying on glycolysis, indicating an inability to adapt fuel sources.
  • AMPK signaling is activated, increasing glycolytic flux via pyruvate dehydrogenase, while enzymes for fatty acid metabolism show reduced activity.

Conclusions:

  • MELAS syndrome cells lack the adaptive mechanism to switch from glucose to fatty acid utilization during energy deficiency.
  • The aberrant activation of the AMPK pathway and impaired fatty acid metabolism contribute to metabolic dyshomeostasis and the clinical phenotype of MELAS syndrome.

Related Concept Videos

Translocation of Proteins into the Mitochondria01:19

Translocation of Proteins into the Mitochondria

Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
13.5K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.1K
ATP Synthase: Mechanism01:48

ATP Synthase: Mechanism

In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
17.4K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
932
Other Glycolytic Pathways01:24

Other Glycolytic Pathways

The pentose phosphate pathway (PPP) operates in parallel with glycolysis, facilitating the metabolism of both pentoses and glucose. This pathway consists of two distinct phases: the oxidative and non-oxidative phases. While it does not directly generate ATP, the intermediates formed during the process can integrate into glycolysis, contributing to cellular energy metabolism when required.Oxidative Phase: NADPH ProductionThe oxidative phase of the pentose phosphate pathway is primarily...
1.0K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
208